ERYTECH Announces Resubmission of European Marketing Authorization Application for GRASPA in Acute Lymphoblastic Leukemia
ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it has resubmitted to the European Medicine Agency (EMA) its Marketing Authorization Application (MAA) for eryaspase (GRASPA®) for the treatment of patients with relapsed or refractory (R/R) acute lymphoblastic leukemia (ALL). The MAA resubmission includes the data from ERYTECH’s GRASPALL 2009-06 Phase 2/3 clinical trial in children and adults with R/R ALL as well as additional data to address the outstanding questions of the Committee for Medicinal Products for Human Use (CHMP) of the EMA.
The GRASPALL Phase 2/3 trial, showed positive efficacy and safety results with GRASPA in combination with chemotherapy as compared to native L-asparaginase in patients with R/R ALL. The patients treated with GRASPA experienced a mean duration of L-asparaginase activity that was almost twice as long as for patients receiving native L-asparaginase. GRASPA also had a favorable safety profile in the trial and no patients who received GRASPA experienced an allergic reaction, as compared to 46% of the patients who received native L-asparaginase. Patients in the GRASPA treatment arm also had overall higher complete remission rates during induction, and GRASPA was associated with fewer drug-related adverse events.
In November 2016, ERYTECH withdrew its original MAA to allow sufficient time to provide the additional data requested in the CHMP’s Day 180 List of Outstanding Issues. ERYTECH has now resubmitted its MAA with additional data from studies on comparability, immunogenicity, and pharmacodynamic effects.
Gil Beyen, CEO and Chairman of ERYTECH, said: "Our teams have worked hard over the past weeks and months to address and compile additional data for the resubmission of the MAA for potential approval of GRASPA as a treatment for ALL. We believe these data have further strengthened our dossier for European marketing authorization. We strongly believe in the potential of our drug candidate and are looking forward to working with the EMA during the review process.”
Dr. Iman El-Hariry, Chief Medical Officer of ERYTECH, added: "We are delighted to complete the resubmission of the MAA for GRASPA in R/R ALL. Asparaginase continues to play an important role in treatment of newly diagnosed patients with R/R ALL. ERYTECH is committed to developing an effective therapy to patients with ALL and improving patient outcomes.”
About Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia (ALL) is a blood cancer affecting mainly the white blood cells. ALL is most prevalent in children between the ages of two and five, although adults are also affected. The American Cancer Society estimates that approximately 5,970 new cases of ALL will be diagnosed in the United States in 2017, resulting in approximately 1,440 deaths. Based on incidence data published in scientific literature, ERYTECH estimates that there are at least as many new cases of ALL diagnosed each year in Europe as in the United States. The risk for developing ALL declines slowly after the age of five until the mid-20s and then begins to rise again slowly after the age of 50. Although most cases of ALL occur in children, approximately 80% of deaths from ALL occur in adults. Pediatric ALL patients have a five-year survival rate of approximately 90%, while the five-year survival rate for adults drops to approximately 30% and for seniors to approximately 15%.
About ERYTECH and eryaspase (GRASPA®): www.erytech.com
Founded in Lyon, France in 2004, ERYTECH is a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside red blood cells, ERYTECH has developed a pipeline of product candidates targeting markets with high unmet medical needs. ERYTECH’s initial focus is on the development of products that target the amino acid metabolism of cancer, depriving them of nutrients necessary for their survival.
The company’s lead product, eryaspase, also known under the trade name GRASPA®, consists of an enzyme, L-asparaginase, encapsulated inside donor-derived red blood cells. L-asparaginase depletes asparagine, a naturally occurring amino acid essential for the survival and proliferation of cancer cells. L-asparaginase has been a standard component of multi-agent chemotherapy for the treatment of acute lymphoblastic leukemia (ALL), but side effects limit treatment, especially in adults and patients with weak performance status. With its improved safety profile, eryaspase aims to provide L-asparaginase to patients who cannot tolerate current non-encapsulated asparaginases.
Eryaspase demonstrated positive efficacy and safety results in various studies in ALL, including in a Phase 2 study in elderly patients with ALL and a Phase 2/3 study in children and adults with relapsed or refractory ALL, as well as in pancreatic cancer, where it achieved positive results in a Phase 2b study of second-line treatment of patients with metastatic pancreatic cancer. ERYTECH believes that the positive results of its Phase 2b clinical study in second-line metastatic pancreatic cancer are significant indicators of eryaspase as a potential treatment approach in solid tumors. ERYTECH also has an ongoing Phase 1 clinical study of eryaspase in the United States in adults with newly diagnosed ALL and a Phase 2b clinical study in Europe in elderly patients with newly diagnosed acute myeloid leukemia (AML), each in combination with chemotherapy.
ERYTECH produces eryaspase at its own GMP-approved and operational manufacturing site in Lyon (France), and at a site for clinical production in Philadelphia (USA). ERYTECH has entered into licensing and distribution partnership agreements for eryaspase for ALL and AML in Europe with Orphan Europe (Recordati Group), and for ALL in Israel with TEVA, which will market the product under the GRASPA® brand name. The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have granted orphan drug designations for eryaspase for the treatment of ALL, AML and pancreatic cancer.
In addition to eryaspase, ERYTECH is developing two other product candidates, erymethionase and eryminase, that focus on using encapsulated enzymes to target cancer metabolism and induce tumor starvation. ERYTECH is also exploring the use of its ERYCAPS platform for developing cancer immunotherapies (ERYMMUNE) and enzyme replacement therapies (ERYZYME).
ERYTECH is listed on Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP) and is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.
This press release contains forward-looking statements, forecasts and estimates with respect to the clinical development plans, business and regulatory strategy, and anticipated future performance of ERYTECH and of the market in which it operates. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. They include all matters that are not historical facts. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond ERYTECH's control. There can be no guarantees with respect to ERYTECH’s resubmission of the MAA or that its product candidates will receive the necessary regulatory approvals or that they will prove to ultimately be commercially successful. Therefore, actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Documents filed by ERYTECH Pharma with the French Autorité des Marchés Financiers (www.amf-france.org), also available on ERYTECH’s website (www.erytech.com) describe such risks and uncertainties. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements. ERYTECH disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in ERYTECH’s expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by law.
Director of Investor Relations
+33 4 78 74 44 38
+1 917 312 5151
The Ruth Group
+1 646 536 7012
+1 508 280 6592
+33 1 44 71 98 52
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Easy Visual Launches App For Targeted Advertising Reach Through Smartphones26.9.2018 10:00 | Tiedote
Easy Visual has launched Banners App - a mobile application that shows targeted banners ads to users when they unlock their smartphones. Recent Boston Consulting Group research indicates that consumers spend 25% of their total offline and online media consumption time on mobile phones. However, advertisers spend only 12% of their budgets on mobile ads. Mobile advertising is unappreciated by some brands and it results in a loss of potential clients. Easy Visual has decided to change the situation. 69% of consumers from 18 to 39 years old use smartphones to look for products before buying them. Banners App offer brands and advertisers ads shown only to their target audiences, real views, statistics on the number of views and the conversion rate. Companies get potential customers, brand recognition and better ROI. It avoids brand reputational loss, because users voluntarily look at the advertising messages. Easy Visual is an innovative advertising network that provides advertisers and bra
SoftAtHome Invests in Quality of Experience for Fixed-Mobile Convergence by Acquiring V3D, Leader in Telecom Data Analytics26.9.2018 10:00 | Tiedote
SoftAtHome, the software company dedicated to the digital home, and V3D, a leading independent software vendor expert on Telecom data analytics for carrier network operators, announced today the signing of an acquisition agreement. With SoftAtHome acquiring V3D, the company will be able to deliver a full range of solutions around “analytics for Quality of Experience” for its fixed and mobile operator clients, by relying on the millions of data points collected by V3D. Thanks to both companies’ expertise, skills and solutions, Carrier Network Operators will benefit from a global value proposition on improving Customer Experience on their fixed and mobile networks. David VIRET-LANGE, Chief Executive Officer of SoftAtHome, commented: “In an increasingly digital world, consumers expect seamless connectivity with their mobile and tablets wherever they are. Quality of Experience will be naturally measured by the same solutions. The V3D solution portfolio and expertise on mobile and fixed net
NeoTract Announces Results from Five Real-World Studies Reaffirming Efficacy and Safety of UroLift® System Treatment for Enlarged Prostate26.9.2018 09:05 | Tiedote
NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced the presentation of new clinical data at the World Congress of Endourology 2018 Annual Conference from five studies of the company’s novel UroLift® System for patients with Benign Prostatic Hyperplasia (BPH). “The real-world results from these studies of diverse patient populations on three continents reaffirm the sustained benefits of the UroLift System as an accepted standard of care treatment for patients with BPH,” said Dave Amerson, president of the NeoTract Interventional Urology business unit. “We are pleased that we continue to see results from real-world studies in line with our randomized pivotal study, demonstrating that the UroLift System is a safe and effective minimally invasive treatment that offers men long-term relief from the symptoms of BPH.” Five Studies Show Significant Relief and Improved Quality of Life with UroLift Sy
NeoTract Announces Results from Two Studies Demonstrating Transformative Benefits of the UroLift® System for BPH Care26.9.2018 09:05 | Tiedote
NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced the presentation of new clinical data at the World Congress of Endourology 2018 Annual Conference from two U.K. studies of the company’s novel UroLift® System for patients with Benign Prostatic Hyperplasia (BPH). “This analysis of the UroLift System demonstrates its transformative impact on BPH care within a major health system,” said Dave Amerson, president of the NeoTract Interventional Urology business unit. “These real-world results continue to support the safety and efficacy of the UroLift System findings of our pivotal trial, and also suggest that the adoption of the UroLift System can save health systems millions in reduced organizational costs when compared to the traditional invasive surgical TURP procedure for patients with BPH.” U.K. Data Suggests UroLift System Greatly Reduces Costs Associated with TURP The Transforming BPH Surgi
Oliver Wyman Supports Inclusion Initiative in the Nordics26.9.2018 09:00 | Tiedote
Oliver Wyman announced today a new partnership with Ashoka, the world’s largest network for social entrepreneurs, to support a new inclusion fund called Hello Nordics. This fall, ten social entrepreneurs – eight from Denmark, Finland, Norway and Sweden and two internationals – will kick off a large-scale inclusion effort across the Nordic region. The entrepreneurs each bring their own unique approach to fostering integration and inclusion. Their common goal: to scale their solutions to better both social and financial inclusion of marginalized people in the Nordic region. The ten entrepreneurs have all been carefully selected based on their ability to address root causes in a systemic way, by involving policy makers, lawmakers, communities and target groups. The participants are Catalysts (NO), Sisters in Business (NO), Foreningen Nydansker (DK), GAME (DK), Startup Refugees (FI), Icehearts (FI), Mitt Liv (SE), Idrott Utan Gränser (SE), Welcoming International (USA/Germany) and ACAF/Win
"Panasonic Prime Smash!" Has Been Given a Complete Makeover - An iPhone, iPad Game That Awakens Children's Interest in Mathematics26.9.2018 06:05 | Tiedote
On August 28, 2018, Panasonic Corporation gave the iPad app, "Panasonic Prime Smash!" a complete makeover. The new release includes the iOS 11 compatible iPhone app as well. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180925006294/en/ The screen of "Panasonic Prime Smash!": In the game, balls with numbers are blown. If it is a prime number, capture it by tapping the ball. (Graphic: Business Wire) [Video] Smartphone game application "Panasonic Prime Smash!" https://channel.panasonic.com/contents/24401/ "Panasonic Prime Smash!" overview "Panasonic Prime Smash!" is a game app that teaches children about the atom of numbers, or prime numbers in a fun, enjoyable way. Balls bearing numbers will appear on the screen one after another. If the number is a prime number, you touch that number. If the number is not a prime number, you "Smash" it, transform it into a prime number, and then touch it. That number will be added to your t
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme